TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: HEROIC (Heparin Requirement in Counterpulsation)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years~* Able to provide consent~* Insertion of Intra-aortic Balloon Pump (IABP) in William Beaumont Hospital (WBH) cath lab~* Anticipated duration of IABP \>/= 18 hours~Exclusion Criteria:~* Contraindications to heparin~* Pre-existing condition requiring heparin administration (other than IABP)~* IABP placed outside of the WBH cardiac catheterization lab prophylactically for high-risk percutaneous coronary intervention (PCI), without complications)~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-Aortic balloon Pump with Heparin (Type: ACTIVE_COMPARATOR): Intra-Aortic Balloon Pump (IABP) with Heparin
- Intra-Aortic balloon Pump without Heparin (Type: ACTIVE_COMPARATOR): Intra-Aortic balloon Pump (IABP) without Heparin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot RCT Feasibility Study: Cancer and T2D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a) 18 years and older~* b) Using pathology reports, a new diagnosis of a solid tumor cancer or lymphoma within the past 3 months~* c) Patients being treated with curative intent or those with a prognosis estimated to be \>2 years, as best assessed by the oncologist.~* d) First medical oncology outpatient visit at UF within the past 3 months~* e) Plans to continue cancer care at UF~* f) Speaks and reads English~* g) Can comply with study related procedures, per the treating oncologist or advanced practice provider~Exclusion Criteria:~* a) Diagnosis of leukemia or pancreatic cancer as the new cancer diagnosis~* b) Being treated for T2D for \> than 3 months~* c) eGFR \<45mL/minute/1.73m2~* d) Liver insufficiency (defined as liver enzymes over 5 times the upper limit of normal or clinical sequelae of advanced cirrhosis as documented by the treating oncologist or Advanced Practice Providers.~* e) Active infection requiring systemic antibiotics~* f) Taking systemic steroids of more than 1-week duration. Must have stopped \>3 days prior to study enrollment. Note, inhaled or topical steroids are not exclusion criteria.~* g) Planning to receive cancer care at a location outside of UF~* h) Enrolled in another study with similar outcomes.~* i) Currently taking metformin or known inability to tolerate it

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Nurse-led (Type: EXPERIMENTAL): Nurse-led (group A). Patients randomized to group A will be taken to an available consultation room within the clinic and provided brief diabetes education which includes understanding what it means to have diabetes, healthy eating, and physical activity. Patients will also receive instructions on how to use a glucometer and how to take Metformin.
- Usual Care (Type: NO_INTERVENTION): Usual Care (Control; group B). Patients randomized to usual care will be informed of their HbA1c value, will continue to receive usual cancer care, and will be encouraged to follow-up with their PCP for T2D management. The RA will ensure that oncology visit clinic notes and the results of the HbA1c testing are relayed to the patient's PCP office. Patients who do not have a PCP identified will be referred to an appropriate provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Polycystic Ovary Syndrome according to Rotterdam criteria,~* BMI ≥ 27 Kg/m2~Exclusion Criteria:~* Type 2 diabetes mellitus,~* in treatment for polycystic ovary syndrome features

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): Metformin 850mg twice a day for six months
- Magnesium (Type: EXPERIMENTAL): Magnesium chloride 250mg daily for six months
- PUFA omega 3 (Type: EXPERIMENTAL): Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EMS Prehospital Blood Culture Collection and Antibiotic Administration: A Two-Phase Pilot Project to Reduce Mortality in Patients With Severe Sepsis and Septic Shock

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Phase 1 (blood culture contamination rate quantification phase)~1. Hemodynamically stable patients ≥18 years old being transported by Lakeview EMS to Lakeview Hospital who will have an intravenous access established as part of their routine prehospital care are eligible for this study.~2. English speaker~Phase 2 (blood cultures + antibiotics prehospital)~a. Patients with fever \>38oC + ≥2 qSOFA who are being transported to Lakeview Hospital that originate as a 911 call~Exclusion Criteria:~Phase 1:~1. Patients age \<18 years~2. Hemodynamic instability~3. Prisoners~Phase 2:~1. Documented allergy to Penicillin or inability to determine patient's medication allergies~2. Prisoners~3. Pregnant patients~4. Patients being transferred from one hospital to another~5. Non-English speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Prehospital intervention (Type: ACTIVE_COMPARATOR): All subjects enrolled in this study will receive a sepsis intervention bundle in the prehospital setting, including blood cultures, IV fluids, and antibiotics. These patients will be compared to historical controls.
- Control arm (Type: NO_INTERVENTION): Historical controls without prehospital sepsis intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Discontinuation Order of Vasopressors in Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients 20 years of age or older~* patients of receiving concomitant therapy with norepinephrine and vasopressin for teh management of septic shock~* patients began to reduce the vasopressor~Exclusion Criteria:~* patients who expired or had care withdrawn while receiving norepinephrine and vasopressin~* patients being transferred into the ICU from an outside facility or the operating room~* patients who are suspected to have vasopressin deficiency (eg. HPA axis dysfunction, empty sella)~* acute myocardial infarction or Congestive heart failure (NYHA functional classification III or IV)~* acute mesenteric ischemia~* patients who were received other vasopressor except for norepinephrine or vasopressin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vasopressin (Type: ACTIVE_COMPARATOR): Vasopressin will be reduced first (0.01 U/hour)
- Norepinephrine (Type: ACTIVE_COMPARATOR): Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving conventional thrice weekly maintenance HD~* Age ≥18 years~* Able to provide informed consent~Exclusion Criteria:~• Not meeting inclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CVInsight Monitoring (Type: EXPERIMENTAL): Single group arm: All participants receive the same intervention/treatment CVInsight non-contact device and CVInsight contact device application.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective laparoscopic hemicolectomy surgery.~* Self-reported Caucasians.~* ASA (American Society of Anesthesiologists) physical status of I or II.~* Agrees to provide signed and dated informed consent form.~* Willingness to agree with the Biobanking policy.~Exclusion Criteria:~* Uncontrolled medical or psychiatric conditions.~* Severe mental impairment.~* History of major depressive disorder, psychotic disorder or schizophrenia, and/or manic episodes within the past year.~* Active alcoholism within the past 6 months.~* Psychoactive recreational drug abuse within the past 6 months including MDMA, Ketamine, hallucinogens such as LSD and/or sympathomimetics such as Cocaine.~* Inability to comprehend pain assessment.~* Pregnancy and/or breast-feeding.~* Known hypersensitivity to Beta Blockers or Opioids.~* Currently taking Propranolol.~* Currently taking other hypotensive treatments.~* Currently taking Opioids.~* Patients with asthma or reactive airway disease.~* Patients with cardiac arrhythmia, coronary artery disease, congestive heart failure.~* Patients with renal failure or dialysis.~* Patients with liver insufficiency.~* Heart rate less than 60bpm or diastolic blood pressure \<50 mmHg during the preoperative visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IV-PCA morphine + Placebo PO (Type: PLACEBO_COMPARATOR): Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial.
- IV-PCA morphine + Propranolol PO (Type: EXPERIMENTAL): The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Location of Hamstring Muscle Lesions in Sport and Relationships With Injury Mechanism.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* To be recreational sportsmen, competitions, amateurs, high-level or professional~* Aged 18 to 50 years~* Perform an Magnetic Resonance Imaging (MRI) or an ultrasound of the thigh in the context of the suspicion of an acute hamstring muscle injury~* Injury during sport since less 21 days old.~Exclusion Criteria:~* a history of surgery of the anterior cruciate ligament with removal of the transplant in the posterior compartment of the thigh~* an antecedent of surgery of the thigh.~* inability to understand the French language for completing the self-questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- hamstring muscle lesions (Type: None): Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Obese (Body Mass Index or BMI greater than or equal to 30 kg/m2) women with PCOS between 18-40 years of age:~   * oligomenorrhea (less than 8 menstrual periods annually)~  * biochemical hyperandrogenemia (elevated total or free testosterone)~  * normal thyroid function tests and serum prolactin; AND~  * exclusion of 21a-hydroxylase deficiency by a fasting 17a-hydroxyprogesterone less than 200 ng/dl.51,~2. acceptable health on the basis of interview, medical history, physical examination, and laboratory tests (Complete Blood Chemistry or CBC, Comprehensive Metabolic Panel denoted SMA20, urinalysis, negative pregnancy test).~3. Signed, witnessed informed consent.~4. Ability to comply with study requirements.~Exclusion Criteria:~1. Diabetes mellitus by fasting glucose or oral glucose tolerance test (OGTT), or clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant disease (other than non-melanoma skin cancer).~2. Current use of oral contraceptives.~3. Documented or suspected recent (within one year) history of drug abuse or alcoholism.~4. Ingestion of any investigational drug within two months prior to study onset.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1/Pioglitazone (Type: EXPERIMENTAL): Pioglitazone in pill form at 45mg twice per day for 6 months
- 2/Placebo (Type: PLACEBO_COMPARATOR): Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tinnitus Related Cerebral Activities

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age limits to \> 18 years and \< 70 years~* Voluntary study participation~* Unhurt of any acute or chronic pathology of the ear (except tinnitus and a possible deafness of perception in the limits fixed below) on the basis of the interrogation and of the clinical examination~* presenting a single sided tinnitus~* Presenting on the side of the tinnitus a phenomenon of residual inhibition with a duration of total disappearance of the tinnitus of more than 30 seconds~* easily reached~* informed consent signed~* Affiliation or recipient with the mode of social security~Exclusion Criteria:~* Subjects incapable to understand the nature and the purposes of the study and/or having difficulty of communication with the investigator~* majors protected by the law or privated of liberty by judiciary or administrative decision~* pregnant woman~* instable tinnitus (difference upper than 3 on mean of the EVA realised during the 5 days before the inclusion)~* insufficient tinnitus intensity (mean of the EVA realised during the 5 days before the inclusion\<4)~* Anomaly of the external or average ear~* Tinnitus attributed to a clearly identified retro-cochlear origin~* Deafness of transmission of more than 15 dB on the tonal audiometry~* Deafness of perception of more than 60 dB in average hearing loss (arithmetic mean) on the frequencies of 0,5-1-2 and 4 kHz.~* Renowned ototoxic treatment during the duration of the protocol (malaria medicines, ototoxic chemotherapy, ototoxic antibiotic treatment),~* Pursuit of a noise exposure of strong intensity with title professional and/or of leisure, dental treatment with use of engine or turbine, during the duration of the protocol.~* Contraindication in the examination MRI (pacemaker, port of surgical clips in the cervico-cephalic region or implanted medical surgical material susceptible to mobilize under the influence of magnetic gradients, foreign body intraocular, pieces of shrapnel at the cervico-cephalic level (possibility of artefact), claustrophobia, pregnancy of less than 3 months)~* History of cranial trauma with encephalic infringement(achievement), ischemic cerebrovascular accident or intracerebral bruise.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- single sided tinnitus (Type: OTHER): patients with single sided tinnitus on which functional brain MRI is assessed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Guided Self-Help for Functional Neurological Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult neurology outpatient with functional symptoms not largely explained by neurologic disease.~Exclusion Criteria:~* Unable to use the Guided Self-Help intervention, such as due to significant cognitive impairment or unable to comprehend English.~* Requires specialist psychiatric care.~* Has headache as the only symptom.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAU+GSH (Type: EXPERIMENTAL): Treatment As Usual plus Guided Self Help.
- TAU (Type: ACTIVE_COMPARATOR): Treatment AS Usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed high-risk/limited stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx~  * Newly diagnosed~ * Previously untreated~ * Considered surgically resectable~ * Evidence of regional lymph node metastases (N1-N3)~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* SGOT or SGPT no greater than 3 times ULN~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative~Renal:~* Creatinine no greater than 2 times ULN~* Creatinine clearance at least 60 mL/min~Other:~* Magnesium normal (magnesium supplement allowed)~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~* HIV negative~* Not pregnant or nursing~* Patients must use effective barrier contraception and prevent bodily fluid transmission during and for 28 days after Ad5CMV-p53 gene administration~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* No concurrent intensity-modulated radiotherapy~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgery with INGN 201 followed by chemo/RT (Type: EXPERIMENTAL): intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues